ACM
CLB icon

AlphaCrest Capital Management’s Core Laboratories CLB Stock Holding History

AlphaCrest Capital Management’s Portfolio CLB Stock Details CLB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-10,600
Closed -$110K – 932
2020
Q1 		$110K Buy
10,600
+1,788
+20% +$50K 0.01% 983
2019
Q4 		$332K Sell
8,812
-9,410
-52% -$423K 0.03% 1008
2019
Q3 		$850K Buy
18,222
+12,699
+230% +$590K 0.05% 659
2019
Q2 		$289K Sell
5,523
-5,900
-52% -$346K 0.03% 871
2019
Q1 		$787K Buy
11,423
+5,423
+90% +$364K 0.12% 272
2018
Q4 		$358K Buy
+6,000
New +$518K 0.11% 376

Other funds holding CLB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

AlphaCrest Capital Management's CLB Position: Q2 2020 in Review

AlphaCrest Capital Management sold out of Core Laboratories (CLB) in Q2 2020, closing a stake of 10,600 shares — an estimated $110K sold.

AlphaCrest Capital Management first reported a position in CLB in Q4 2018 and held it in 6 quarters. The position peaked at $850K in Q3 2019. 197 funds tracked by Wall St. Rank hold CLB as of Q2 2020.

  • AlphaCrest Capital Management reported no remaining Core Laboratories position as of Q2 2020 after selling out during the quarter.
  • AlphaCrest Capital Management sold 10,600 Core Laboratories shares in Q2 2020, an estimated $110K.
  • AlphaCrest Capital Management first reported a position in Core Laboratories in Q4 2018 and held it in 6 quarters.
  • AlphaCrest Capital Management's Core Laboratories position peaked at $850K in Q3 2019.
  • 197 funds tracked by Wall St. Rank held Core Laboratories as of Q2 2020.

Based on AlphaCrest Capital Management's 13F filing for Q2 2020, filed 12 Aug 2020.